Humana Inc. (NYSE:HUM) had its target price upped by equities research analysts at Bank of America Corporation from $270.00 to $275.00 in a report released on Friday. The firm currently has a “buy” rating on the insurance provider’s stock. Bank of America Corporation’s price target suggests a potential upside of 15.03% from the stock’s current price.

A number of other brokerages have also recently issued reports on HUM. Credit Suisse Group reaffirmed an “outperform” rating and issued a $250.00 price objective (up previously from $245.00) on shares of Humana in a research note on Thursday. Citigroup Inc. assumed coverage on shares of Humana in a research note on Wednesday, June 28th. They issued a “buy” rating and a $275.00 price objective for the company. UBS AG reaffirmed a “neutral” rating and issued a $237.00 price objective (up previously from $205.00) on shares of Humana in a research note on Wednesday, June 28th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Humana in a research note on Friday, June 23rd. Finally, Morgan Stanley assumed coverage on shares of Humana in a research note on Tuesday, June 6th. They issued an “overweight” rating and a $262.00 price objective for the company. Nine investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $231.00.

Shares of Humana (NYSE HUM) traded up 0.42% during trading on Friday, hitting $239.07. 1,126,881 shares of the stock were exchanged. Humana has a 52 week low of $150.00 and a 52 week high of $241.33. The firm has a market capitalization of $34.50 billion, a price-to-earnings ratio of 24.37 and a beta of 0.91. The stock’s 50 day moving average price is $232.54 and its 200 day moving average price is $215.15.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, May 3rd. The insurance provider reported $2.75 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.55 by $0.20. Humana had a net margin of 2.71% and a return on equity of 14.38%. The company had revenue of $13.76 billion during the quarter, compared to analysts’ expectations of $13.61 billion. During the same quarter in the prior year, the company earned $1.86 EPS. On average, equities analysts predict that Humana will post $11.15 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, July 31st. Stockholders of record on Friday, June 30th will be given a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, June 28th. This represents a $1.60 annualized dividend and a dividend yield of 0.67%. Humana’s dividend payout ratio is 16.24%.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/07/15/humana-inc-nysehum-price-target-increased-to-275-00-by-analysts-at-bank-of-america-corporation.html.

In related news, CEO Bruce D. Broussard sold 118,231 shares of the stock in a transaction dated Thursday, May 4th. The shares were sold at an average price of $225.82, for a total value of $26,698,924.42. Following the completion of the transaction, the chief executive officer now directly owns 171,170 shares in the company, valued at approximately $38,653,609.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Brian P. Leclaire sold 4,971 shares of the stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the completion of the transaction, the senior vice president now owns 14,258 shares of the company’s stock, valued at $3,421,920. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 143,241 shares of company stock valued at $32,446,903. Corporate insiders own 0.80% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Guardian Life Insurance Co. of America raised its position in shares of Humana by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock valued at $119,000 after buying an additional 4 shares during the last quarter. Independent Portfolio Consultants Inc. raised its position in shares of Humana by 22.1% in the second quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock valued at $125,000 after buying an additional 94 shares during the last quarter. Point72 Asia Hong Kong Ltd acquired a new position in shares of Humana during the first quarter valued at about $128,000. MUFG Americas Holdings Corp acquired a new position in shares of Humana during the first quarter valued at about $221,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Humana during the first quarter valued at about $223,000. Institutional investors own 98.90% of the company’s stock.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.